---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incidence"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incidence. Topics: US adults with newly coded NASH with F2 to F3 fibrosis: claims-based annual incidence, 2020; US adults with NASH: incident and prevalent cases in 2017, Markov model; Adults with fatty liver developing NASH: paired biopsy and imaging meta-analysis of observational studies; US incident NAFL cases, 2015 and projected to 2030, Markov model; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/incidence"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-2.2.1.2.1-1"></a>

### US adults with newly coded NASH with F2 to F3 fibrosis: claims-based annual incidence, 2020

> “In the base case, the annual incidence was calculated by dividing the projected number of newly coded patients with F2/F3 NASH in 2020 (73,085) in the US population by the total adult population (257,279,447), resulting in a rate of 28.4 cases per 100,000 adults”
> “other diagnosed NASH incidence rates were obtained from analyses conducted using the Optum CDM and Veradigm® EHR (linked with Komodo Health claims), which provided a range of values (20.4–64.0 per 100,000 adults)”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.2.1-2"></a>

### US adults with NASH: incident and prevalent cases in 2017, Markov model

> “Our models estimated that there are 6.65 million adults (18+ years old) with NASH in the United States and that there were 232,000 incident cases in 2017.”

Source: [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/)

<a id="topic-2.2.1.2.1-3"></a>

### Adults with fatty liver developing NASH: paired biopsy and imaging meta-analysis of observational studies

> “We screened 9,744 articles and included 54 studies involving 26,738 patients.”
> “In addition, 31% of patients developed NASH after 4.7 years (incidence rate=7.4/100 person-years) whereas in 29% of those with NASH, resolution occurred after a median of 3.5 years (incidence rate=5.1/100 person-years).”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.1.2.1-4"></a>

### US incident NAFL cases, 2015 and projected to 2030, Markov model

> “In 2015, an estimated 3.44 million incident NAFL cases occurred. By 2030, incident NAFL cases decreased 31% to 2.50 million.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.2.1-5"></a>

### Global NAFLD incidence in adults diagnosed by imaging: meta-analysis

> “The overall incidence of NAFLD was estimated to be 46·9 cases per 1000 person-years (36·4-57·5); 70·8 cases per 1000 person-years (48·7-92·8) in men and 29·6 cases per 1000 person-years (20·2-38·9) in women (p<0·0001).”

Source: [Riazi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35798021/)

<a id="topic-2.2.1.2.1-6"></a>

### Global NAFLD incidence in ultrasound-diagnosed cohorts: meta-analysis of 12 studies

> “Incidence rates were reported in 12 studies involving a total sample size of 256,757 subjects at baseline with total PY of 800,853. The pooled incidence estimate of NAFLD was 48.89 per 1000 PY.”
> “The pooled NAFLD incidence numerically increased by +58.0% from 37.41 per 1000 PY (95% CI: 24.36–57.06) in 1994–2006 to 59.11 per 1000 (39.64–87.26) in 2010–2014 survey year”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
